12.1 Non-Sterile Compounding Standards: USP <795>, Beyond-Use Dating & Alabama Standards

12.1 Non-Sterile Compounding Standards: USP <795>, Beyond-Use Dating & Alabama Standards

[!NOTE] Dual Federal and State Regulatory Framework: Compounding pharmacy practice in Alabama is governed simultaneously by federal statutes—specifically Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 353a) added by the Drug Quality and Security Act (DQSA) of 2013—and state rules codified in the Alabama Pharmacy Practice Act (Ala. Code 1975 § 34-23-1 et seq.) and Alabama Administrative Code (Ala. Admin. Code r. 680-X-2-.43: Drug Compounding). In addition, United States Pharmacopeia (USP) General Chapter <795> sets enforceable federal and state standards for non-sterile compounding.

Compounding is an essential component of pharmacy practice that provides customized therapeutic formulations for patients whose clinical needs cannot be met by commercially manufactured, FDA-approved drug products. However, because compounded preparations do not undergo FDA premarket review for safety and efficacy, federal and state laws enforce rigorous operational, documentation, and beyond-use dating boundaries to safeguard public health.

---

Statutory Compounding Architecture: Section 503A vs. Section 503B

Title I of the Drug Quality and Security Act (Compounding Quality Act) established a clear statutory bifurcation between traditional state-regulated compounding pharmacies and federally regulated outsourcing facilities.

+---------------------------------------------------------------------------------------------------------+
|                               Federal Compounding Regulatory Bifurcation                                |
+---------------------------------------------------------------------------------------------------------+
| Dimension                  | Section 503A (Traditional Pharmacy)       | Section 503B (Outsourcing Facility)     |
|----------------------------+-------------------------------------------+-----------------------------------------|
| Primary Regulator          | State Boards of Pharmacy (e.g., ALBOP)    | Food and Drug Administration (FDA)      |
| Patient-Specific Rx        | MANDATORY (or limited anticipatory)       | NOT required (office stock compounding) |
| CGMP Compliance (Part 211) | EXEMPT (Governed by USP compendia)        | MANDATORY (Full federal CGMP compliance)|
| FDA Premarket Approval     | EXEMPT (No NDA or ANDA required)          | EXEMPT (No NDA or ANDA required)        |
| Adequate Directions Label  | EXEMPT (State prescription label applies) | EXEMPT (Special 503B labeling applies)  |
| Interstate Distribution    | Capped at 5% unless state MoU signed      | Permitted without percentage limitation |
| Operational Registration   | Standard ALBOP Pharmacy Permit            | Voluntary Federal 503B Registration     |
+---------------------------------------------------------------------------------------------------------+

Traditional Compounding: Section 503A

To qualify for the statutory exemptions under 21 U.S.C. § 353a (exemptions from CGMP, FDA premarket approval, and mandatory labeling with adequate directions for use), a pharmacy must satisfy strict criteria:

1. Patient-Specific Prescription: Compounding must be performed pursuant to a valid prescription order for an identified individual patient.
2. Anticipatory Compounding: Compounding in limited quantities before receiving a valid prescription order is permitted only if based on a history of receiving valid prescriptions generated by an established relationship between the pharmacist, patient, and prescriber.
3. Prohibition on Commercially Available Copies: A pharmacy cannot compound preparations that are essentially copies of commercially available drug products on a regular basis or in inordinate quantities. An exception exists only if there is a change made for an individual patient that produces a significant difference (e.g., liquid dosage form for a patient with severe dysphagia who cannot swallow tablets, or removing an excipient, dye, or preservative due to a documented allergy) as determined and documented by the prescribing practitioner, or if the commercial product is listed on the official FDA Drug Shortages database.
4. Prohibition on Compounding for Wholesale: Compounded preparations cannot be distributed for resale or wholesale by third parties.
5. Bulk Substance Quality: Active Pharmaceutical Ingredients (APIs) must comply with USP-NF monographs, be manufactured by an FDA-registered establishment, and be accompanied by a valid Certificate of Analysis (CoA).

Outsourcing Facilities: Section 503B

Under 21 U.S.C. § 353b, an entity that compounds sterile (and optional non-sterile) drugs may register voluntarily with the FDA as an outsourcing facility:

• 503B facilities can compound and distribute medications in bulk for office use without patient-specific prescriptions.
• They are not exempt from Current Good Manufacturing Practice (CGMP, 21 C.F.R. Part 211), meaning they operate under continuous industrial-grade environmental monitoring, process validation, and batch release testing.
• They are subject to risk-based FDA inspections, must report all compounded products to the FDA every six months, and must report serious adverse events to the FDA within fifteen (15) calendar days.

---

Alabama State Compounding Standards (Ala. Admin. Code r. 680-X-2-.43)

The Alabama State Board of Pharmacy enforces strict administrative regulations governing all pharmacies holding an ALBOP permit that engage in drug compounding:

The Prescriber Office-Use Restriction

A critical, heavily tested distinction in Alabama jurisprudence concerns medication compounded for "office use":

• Under federal Section 503A interpretation and ALBOP enforcement, traditional pharmacies cannot compound medications in bulk and distribute them to physicians or clinics for general "office use" without an individualized patient-specific prescription.
• If a prescriber in Alabama requires non-patient-specific compounded medications for routine clinic administration, those medications must be sourced from an FDA-registered Section 503B outsourcing facility holding an active non-resident permit with ALBOP.
• Compounding preparations for resale or distribution to other retail pharmacies, wholesalers, or brokers is strictly unlawful and constitutes unlicensed drug manufacturing.

Documented Medical Necessity for Copies

Under Ala. Admin. Code r. 680-X-2-.43, a pharmacist may not compound any product that is commercially available unless:

• The commercial product is currently unavailable due to a verified pharmaceutical supply chain shortage; or
• The prescriber specifies in the order a specific medical rationale demonstrating that the commercially available dosage form cannot be tolerated or utilized by that particular patient.
• Economic Rationale Prohibited: Compounding a commercially available formulation solely because it is less expensive to compound than to purchase from a commercial manufacturer is strictly unlawful under both Section 503A and Alabama law.

---

Compounding Documentation: Master Formulation Records vs. Compounding Records

USP <795> and ALBOP rules require two distinct, non-interchangeable tiers of documentation for non-sterile compounded preparations: the Master Formulation Record (MFR) and the Compounding Record (CR).

                                  Compounding Documentation Architecture

        Master Formulation Record (MFR)                        Compounding Record (CR)
        [The Invariant Recipe / Blueprint]                    [The Batch Execution Record]
        ┌────────────────────────────────┐                    ┌────────────────────────────────┐
        │ • Official name, strength, form│                    │ • Reference to source MFR      │
        │ • Calculations & formulas      │                    │ • Actual weights & volumes     │
        │ • Invariant ingredient list    │                    │ • Specific lot #s & exp dates  │
        │ • Equipment & container type   │ ───Generates──────►│ • Person who compounded        │
        │ • Step-by-step mixing directions│                    │ • Supervising RPh signature    │
        │ • Quality control criteria     │                    │ • Unique internal batch/Rx #   │
        │ • Sample label format          │                    │ • Assigned BUD & rationale     │
        │ • Assigned default BUD rationale│                   │ • Duplicate of actual label    │
        └────────────────────────────────┘                    └────────────────────────────────┘

Master Formulation Record (MFR)

The MFR is the established, permanent "recipe" that must be created prior to compounding a preparation for the first time. It is an invariant standard operating procedure that provides the detailed instructions necessary to replicate the compounded drug uniformly across different compounding events. Mandatory MFR components include:

1. Name, strength, and dosage form of the preparation;
2. Identities, purity grades, and exact quantities of all active ingredients and excipients;
3. Equipment, measuring tools, and utensils required;
4. Container-closure specifications and packaging requirements;
5. Step-by-step mixing, heating, cooling, and compounding instructions;
6. Sample labeling layout, including mandatory auxiliary warnings;
7. Assigned Beyond-Use Date (BUD) and the published scientific or compendial stability reference used to justify it;
8. Physical quality control checks (e.g., color, odor, clarity, pH range, visual uniformity) and expected yield.

Compounding Record (CR)

The CR is the dynamic, batch-specific audit document that must be completed each time a preparation is compounded. It records the actual execution of the compounding process for a specific patient or anticipatory batch. Mandatory CR components include:

1. Official name, strength, and dosage form matching the MFR;
2. Cross-reference to the specific Master Formulation Record used;
3. Unique internal identification number (prescription number or batch lot number);
4. Exact manufacturer, internal lot number, and manufacturer expiration date for every individual component, active ingredient, and excipient utilized;
5. Actual measured weights, volumes, and quantities of every component;
6. Total quantity or yield compounded;
7. Full legal signature or initials of the pharmacy technician or intern who compounded the preparation;
8. Full legal signature or initials of the supervising licensed pharmacist who conducted final verification;
9. Date and time of compounding and verification;
10. Assigned Beyond-Use Date (BUD);
11. Duplicate of the actual container label affixed to the dispensed package; and
12. Documentation of any deviations from the MFR or quality control results.

---

Beyond-Use Dating (BUD) Under Revised USP <795> (2023 Revision)

A beyond-use date (BUD) represents the date or hour after which a compounded non-sterile preparation (CNSP) must not be used, stored, or transported. Under the revised USP <795> standards, in the absence of a specific USP-NF monograph or valid stability-indicating analytical literature, default BUDs are determined based on water activity ($a_w$), the presence of an antimicrobial preservative, and the storage condition.

Crucial Universal Principle: Component Expiration Cap

$\text{Maximum Allowable BUD} \le \min(\text{USP } <795> \text{ Category Limit}, \text{ Earliest Expiration Date of Any Component})$

Under no circumstances can an assigned BUD extend beyond the earliest manufacturer expiration date of any individual active pharmaceutical ingredient (API) or excipient used in the preparation.

Revised USP <795> Default Beyond-Use Dating Hierarchy

Detailed Analysis of Dosage Form Categories

1. Non-Preserved Aqueous Dosage Forms ($a_w \ge 0.60$):
   • Preparations where water is a continuous phase or freely available to support microbial growth and that lack an effective preservative system (e.g., pediatric oral suspensions prepared with water, simple syrups, or unpreserved vehicles).
   • Must be labeled with a maximum BUD of fourteen (14) days and must be stored under refrigeration ($2^\circ\text{C to } 8^\circ\text{C}$) at all times.
2. Preserved Aqueous Dosage Forms ($a_w \ge 0.60$):
   • Preparations formulated with an aqueous phase that include an effective antimicrobial preservative (such as methylparaben, propylparaben, sodium benzoate, or potassium sorbate) at an established inhibitory concentration.
   • May be assigned a maximum BUD of thirty-five (35) days stored either at controlled room temperature ($20^\circ\text{C to } 25^\circ\text{C}$) or under refrigeration ($2^\circ\text{C to } 8^\circ\text{C}$).
3. Non-Aqueous Liquids and Semi-Solids ($a_w < 0.60$):
   • Formulations that contain no water or have a water activity below 0.60, such as mineral oil or vegetable oil suspensions, anhydrous topical ointments (e.g., white petrolatum or Aquaphor bases), and non-aqueous gels.
   • Maximum default BUD of ninety (90) days stored at controlled room temperature.
4. Solid Dosage Forms ($a_w < 0.60$):
   • Capsules, compressed tablets, powders for reconstitution, and molded suppositories.
   • Maximum default BUD of one hundred eighty (180) days stored at controlled room temperature.

---

Facility Requirements, Equipment Calibration & Quality Assurance

USP <795> and Alabama Board rules mandate dedicated operational controls to ensure non-sterile compounding safety:

• Designated Compounding Area: Compounding must occur in a dedicated space separated from general dispensing traffic. Surfaces (countertops, shelving, walls) must be smooth, non-porous, impervious, and easy to sanitize.
• Plumbing and Water Sources: The compounding area must have access to potable water and a dedicated sink with hot and cold running water for handwashing and equipment cleaning. Purified water (USP grade) must be utilized for compounding non-sterile preparations when water is an ingredient.
• Equipment Calibration:
  • Class A prescription balances (or electronic analytical balances) must be inspected, calibrated, and certified at least annually. Electronic balances must undergo daily routine zero/drift verification prior to use.
  • Graduated cylinders must be made of borosilicate glass or non-reactive plastic. When measuring liquids, the volume measured must represent at least 20% of the cylinder's total capacity to avoid volumetric error.
• Personnel Training and Competency Assessment:
  • Compounding personnel (pharmacists, registered interns, and technicians) must complete initial training and pass a comprehensive competency evaluation before compounding independently.
  • Re-evaluation must occur at least once every twelve (12) months (annually), covering hand hygiene, proper garbing, measuring and mixing techniques, cleaning protocols, standard operating procedure (SOP) compliance, and documentation precision.
• Record Retention: In Alabama, all compounding documentation—including MFRs, CRs, equipment calibration logs, chemical certificates of analysis, and personnel training files—must be maintained and readily retrievable for a minimum statutory period of two (2) years.